Cargando…
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
SIMPLE SUMMARY: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773938/ https://www.ncbi.nlm.nih.gov/pubmed/35053494 http://dx.doi.org/10.3390/cancers14020331 |
_version_ | 1784636221076537344 |
---|---|
author | Mimori, Tomoyasu Shukuya, Takehito Ko, Ryo Okuma, Yusuke Koizumi, Tomonobu Imai, Hisao Takiguchi, Yuichi Miyauchi, Eisaku Kagamu, Hiroshi Sugiyama, Tomohide Azuma, Keisuke Namba, Yukiko Yamasaki, Masahiro Tanaka, Hisashi Takashima, Yuta Soda, Sayo Ishimoto, Osamu Koyama, Nobuyuki Kobayashi, Kunihiko Takahashi, Kazuhisa |
author_facet | Mimori, Tomoyasu Shukuya, Takehito Ko, Ryo Okuma, Yusuke Koizumi, Tomonobu Imai, Hisao Takiguchi, Yuichi Miyauchi, Eisaku Kagamu, Hiroshi Sugiyama, Tomohide Azuma, Keisuke Namba, Yukiko Yamasaki, Masahiro Tanaka, Hisashi Takashima, Yuta Soda, Sayo Ishimoto, Osamu Koyama, Nobuyuki Kobayashi, Kunihiko Takahashi, Kazuhisa |
author_sort | Mimori, Tomoyasu |
collection | PubMed |
description | SIMPLE SUMMARY: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on patient characteristics, progression-free survival (PFS), overall survival (OS), and tumor marker values, and investigated the relationship between tumor marker values and PFS/OS. We found that the neuron-specific enolase (NSE) level may be a useful prognostic tumor marker for ATC, regardless of histology. The findings of the analysis limited to squamous cell carcinoma suggested that the NSE and squamous cell carcinoma antigen levels may be useful prognostic factors. ABSTRACT: The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan–Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05–2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31–3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology. |
format | Online Article Text |
id | pubmed-8773938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87739382022-01-21 Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study Mimori, Tomoyasu Shukuya, Takehito Ko, Ryo Okuma, Yusuke Koizumi, Tomonobu Imai, Hisao Takiguchi, Yuichi Miyauchi, Eisaku Kagamu, Hiroshi Sugiyama, Tomohide Azuma, Keisuke Namba, Yukiko Yamasaki, Masahiro Tanaka, Hisashi Takashima, Yuta Soda, Sayo Ishimoto, Osamu Koyama, Nobuyuki Kobayashi, Kunihiko Takahashi, Kazuhisa Cancers (Basel) Article SIMPLE SUMMARY: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on patient characteristics, progression-free survival (PFS), overall survival (OS), and tumor marker values, and investigated the relationship between tumor marker values and PFS/OS. We found that the neuron-specific enolase (NSE) level may be a useful prognostic tumor marker for ATC, regardless of histology. The findings of the analysis limited to squamous cell carcinoma suggested that the NSE and squamous cell carcinoma antigen levels may be useful prognostic factors. ABSTRACT: The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan–Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05–2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31–3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology. MDPI 2022-01-11 /pmc/articles/PMC8773938/ /pubmed/35053494 http://dx.doi.org/10.3390/cancers14020331 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mimori, Tomoyasu Shukuya, Takehito Ko, Ryo Okuma, Yusuke Koizumi, Tomonobu Imai, Hisao Takiguchi, Yuichi Miyauchi, Eisaku Kagamu, Hiroshi Sugiyama, Tomohide Azuma, Keisuke Namba, Yukiko Yamasaki, Masahiro Tanaka, Hisashi Takashima, Yuta Soda, Sayo Ishimoto, Osamu Koyama, Nobuyuki Kobayashi, Kunihiko Takahashi, Kazuhisa Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study |
title | Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study |
title_full | Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study |
title_fullStr | Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study |
title_full_unstemmed | Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study |
title_short | Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study |
title_sort | clinical significance of tumor markers for advanced thymic carcinoma: a retrospective analysis from the nej023 study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773938/ https://www.ncbi.nlm.nih.gov/pubmed/35053494 http://dx.doi.org/10.3390/cancers14020331 |
work_keys_str_mv | AT mimoritomoyasu clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT shukuyatakehito clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT koryo clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT okumayusuke clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT koizumitomonobu clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT imaihisao clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT takiguchiyuichi clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT miyauchieisaku clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT kagamuhiroshi clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT sugiyamatomohide clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT azumakeisuke clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT nambayukiko clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT yamasakimasahiro clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT tanakahisashi clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT takashimayuta clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT sodasayo clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT ishimotoosamu clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT koyamanobuyuki clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT kobayashikunihiko clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study AT takahashikazuhisa clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study |